CanSino Biologics Inc.

CanSino Biologics Inc.

CASBF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$765.84M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
CanSino Biologics Inc.CanSino Biologics Inc.592.4-1%0.60.2

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$765.84 Million
Enterprise Value$577.88 Million
Earnings per Share$0.11
Beta1.16
Outstanding Shares247,043,801

Return

Return on Equity0.59%ROE
Return on Assets0.43%
Return on Invested Capital-0.85%

Valuation & Multiples

P/E Ratio592.43P/E Ratio
PEG-1515.57PEG
Price to Sales0.62Price to Sales
Price to Book Ratio0.16Price to Book Ratio
Enterprise Value to Revenue0.46
Enterprise Value to EBIT-11.22
Enterprise Value to Net Income19
Total Debt to Enterprise1.63
Debt to Equity0.19Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
October 28, 2026
EPS Estimate
$0.04
Consensus analyst estimate
Revenue Estimate
$59.47 M
Consensus analyst estimate

Next Earnings Call

Expected Date
March 30, 2027
EPS Estimate
$0.05
Consensus analyst estimate
Revenue Estimate
$84.20 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About CanSino Biologics Inc.

1,175 employees
CEO: Xue Feng Yu

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an...